Zydus Lifesciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	285,917	271,484	232,415	195,474	172,374	151,099
Revenue Growth	21.11%	16.81%	18.90%	13.40%	14.08%	4.90%
Cost of Revenue	79,739	75,236	65,384	63,937	64,707	56,857
Gross Profit	206,178	196,248	167,031	131,537	107,667	94,242
Selling, General & Admin	68,341	64,711	50,001	42,454	37,648	32,472
Other Operating Expenses	66,977	59,088	48,264	36,047	34,263	29,873
Operating Expenses	152,684	137,999	107,429	86,145	79,139	69,501
Operating Income	53,494	58,249	59,602	45,392	28,528	24,741
Interest Expense	-4,363	-3,650	-935	-440	-1,255	-1,144
Interest & Investment Income	4,237	4,237	1,862	1,281	768	696
Earnings From Equity Investments	1,005	971	578	1,184	946	462
Currency Exchange Gain (Loss)	12,803	12,805	1,634	806	2,843	1,482
Other Non Operating Income (Expenses)	-437	51	31	-11	251	622
EBT Excluding Unusual Items	66,739	72,663	62,772	48,212	32,081	26,859
Merger & Restructuring Charges	-1,336	-245	-	-177	-101	-
Impairment of Goodwill	-	-	-1,350	-	-5,941	-
Gain (Loss) on Sale of Investments	292	292	590	1,385	596	874
Gain (Loss) on Sale of Assets	23	23	345	134	208	-17
Asset Writedown	-	-	-846	-	-	-
Legal Settlements	-3,066	-3,975	-	-	-	-
Other Unusual Items	-1,576	-1,576	-666	-281	-	1,127
Pretax Income	61,076	67,182	60,845	49,273	26,843	28,843
Income Tax Expense	15,149	15,947	14,119	9,775	5,878	5,117
Earnings From Continuing Operations	45,927	51,235	46,726	39,498	20,965	23,726
Earnings From Discontinued Operations	-	-	-	230	-46	22,457
Net Income to Company	45,927	51,235	46,726	39,728	20,919	46,183
Minority Interest in Earnings	-797	-835	-1,471	-1,133	-1,316	-1,310
Net Income	45,130	50,400	45,255	38,595	19,603	44,873
Net Income to Common	45,130	50,400	45,255	38,595	19,603	44,873
Net Income Growth	-1.30%	11.37%	17.26%	96.88%	-56.31%	110.32%
Shares Outstanding (Basic)	1,006	1,006	1,006	1,012	1,016	1,024
Shares Outstanding (Diluted)	1,006	1,006	1,006	1,012	1,016	1,024
Shares Change	-0.02%	-	-0.56%	-0.37%	-0.79%	-
EPS (Basic)	44.86	50.09	44.97	38.14	19.30	43.83
EPS (Diluted)	44.86	50.09	44.97	38.14	19.30	43.83
EPS Growth	-1.28%	11.37%	17.92%	97.61%	-55.97%	110.32%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-	-12,774	50,874	22,897	16,579	9,019
Free Cash Flow Per Share	-	-12.70	50.56	22.63	16.32	8.81
Dividend Per Share	-	1.000	11.000	3.000	6.000	2.500
Dividend Growth	-	-90.91%	266.67%	-50.00%	140.00%	-28.57%
Gross Margin	72.11%	72.29%	71.87%	67.29%	62.46%	62.37%
Operating Margin	18.71%	21.46%	25.64%	23.22%	16.55%	16.37%
Profit Margin	15.78%	18.57%	19.47%	19.74%	11.37%	29.70%
Free Cash Flow Margin	-	-4.71%	21.89%	11.71%	9.62%	5.97%
EBITDA	68,065	71,646	68,303	52,572	35,344	31,695
EBITDA Margin	23.81%	26.39%	29.39%	26.90%	20.50%	20.98%
D&A For EBITDA	14,571	13,397	8,701	7,180	6,816	6,954
EBIT	53,494	58,249	59,602	45,392	28,528	24,741
EBIT Margin	18.71%	21.46%	25.64%	23.22%	16.55%	16.37%
Effective Tax Rate	24.80%	23.74%	23.21%	19.84%	21.90%	17.74%
Revenue as Reported	290,524	276,579	235,110	198,315	174,240	153,346
Advertising Expenses	-	6,096	3,368	2,957	2,573	2,514